Maurizio Zangari
Concepts (496)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 152 | 2026 | 3082 | 9.880 |
Why?
| | Thalidomide | 33 | 2016 | 378 | 2.810 |
Why?
| | Boronic Acids | 17 | 2013 | 180 | 2.650 |
Why?
| | Pyrazines | 17 | 2013 | 188 | 2.640 |
Why?
| | Bone Marrow | 17 | 2022 | 359 | 1.780 |
Why?
| | Hematopoietic Stem Cell Transplantation | 21 | 2024 | 610 | 1.750 |
Why?
| | Venous Thrombosis | 8 | 2009 | 91 | 1.590 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 31 | 2024 | 1043 | 1.570 |
Why?
| | Paraproteinemias | 7 | 2022 | 72 | 1.500 |
Why?
| | Angiogenesis Inhibitors | 12 | 2009 | 186 | 1.440 |
Why?
| | Humans | 166 | 2026 | 53230 | 1.320 |
Why?
| | Antibodies, Bispecific | 7 | 2025 | 108 | 1.300 |
Why?
| | Protease Inhibitors | 7 | 2011 | 59 | 1.250 |
Why?
| | Chromosomes, Human, Pair 1 | 7 | 2023 | 95 | 1.220 |
Why?
| | Prognosis | 42 | 2025 | 2118 | 1.180 |
Why?
| | Proteasome Inhibitors | 6 | 2016 | 104 | 1.170 |
Why?
| | Aged | 68 | 2026 | 10429 | 1.160 |
Why?
| | Middle Aged | 71 | 2026 | 13419 | 1.160 |
Why?
| | Neoplasm, Residual | 7 | 2025 | 171 | 1.100 |
Why?
| | Antineoplastic Agents | 20 | 2024 | 1232 | 1.090 |
Why?
| | Alkaline Phosphatase | 7 | 2020 | 92 | 1.080 |
Why?
| | Thrombosis | 6 | 2013 | 250 | 0.990 |
Why?
| | Transplantation, Autologous | 29 | 2024 | 488 | 0.990 |
Why?
| | Bone Diseases | 2 | 2021 | 94 | 0.970 |
Why?
| | Bone Remodeling | 3 | 2016 | 154 | 0.960 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 9 | 2025 | 123 | 0.920 |
Why?
| | Male | 78 | 2026 | 27435 | 0.920 |
Why?
| | Female | 77 | 2026 | 28782 | 0.900 |
Why?
| | Osteogenesis | 4 | 2018 | 374 | 0.870 |
Why?
| | Gene Expression Profiling | 22 | 2025 | 1112 | 0.850 |
Why?
| | Immunologic Factors | 5 | 2016 | 117 | 0.840 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 6 | 2012 | 59 | 0.770 |
Why?
| | Anticoagulants | 6 | 2009 | 280 | 0.760 |
Why?
| | Neoplasms, Plasma Cell | 4 | 2024 | 35 | 0.760 |
Why?
| | Melphalan | 12 | 2016 | 180 | 0.760 |
Why?
| | Adult | 46 | 2026 | 14534 | 0.730 |
Why?
| | Activated Protein C Resistance | 4 | 2011 | 10 | 0.730 |
Why?
| | Parathyroid Hormone | 4 | 2018 | 149 | 0.700 |
Why?
| | Antibodies, Monoclonal | 4 | 2022 | 477 | 0.690 |
Why?
| | Aged, 80 and over | 24 | 2026 | 3494 | 0.680 |
Why?
| | Venous Thromboembolism | 3 | 2011 | 78 | 0.680 |
Why?
| | Plasma Cells | 10 | 2025 | 234 | 0.650 |
Why?
| | Durapatite | 1 | 2020 | 23 | 0.650 |
Why?
| | B-Cell Maturation Antigen | 7 | 2025 | 101 | 0.640 |
Why?
| | Retrospective Studies | 27 | 2026 | 6819 | 0.630 |
Why?
| | Disease-Free Survival | 21 | 2019 | 466 | 0.630 |
Why?
| | Thromboembolism | 3 | 2009 | 48 | 0.620 |
Why?
| | Gene Amplification | 1 | 2019 | 58 | 0.620 |
Why?
| | Survival Rate | 21 | 2020 | 949 | 0.610 |
Why?
| | Neoplasm Proteins | 7 | 2020 | 330 | 0.610 |
Why?
| | Dexamethasone | 14 | 2024 | 429 | 0.610 |
Why?
| | Myeloablative Agonists | 4 | 2012 | 32 | 0.600 |
Why?
| | Disease Progression | 17 | 2025 | 880 | 0.570 |
Why?
| | Gene Expression Regulation, Neoplastic | 12 | 2021 | 868 | 0.570 |
Why?
| | Factor V | 4 | 2011 | 10 | 0.560 |
Why?
| | Oligopeptides | 3 | 2018 | 94 | 0.560 |
Why?
| | Bone and Bones | 4 | 2021 | 501 | 0.560 |
Why?
| | Spinal Fractures | 1 | 2018 | 37 | 0.560 |
Why?
| | Thymus Gland | 1 | 2018 | 39 | 0.550 |
Why?
| | Parathyroidectomy | 1 | 2018 | 46 | 0.540 |
Why?
| | Thyroidectomy | 1 | 2018 | 61 | 0.540 |
Why?
| | Translocation, Genetic | 8 | 2021 | 266 | 0.530 |
Why?
| | Risk Factors | 24 | 2026 | 4017 | 0.530 |
Why?
| | Clinical Trials as Topic | 9 | 2022 | 466 | 0.530 |
Why?
| | Chromosome Aberrations | 11 | 2023 | 297 | 0.520 |
Why?
| | Survival Analysis | 14 | 2024 | 659 | 0.520 |
Why?
| | Treatment Outcome | 31 | 2022 | 5595 | 0.520 |
Why?
| | Calcification, Physiologic | 1 | 2017 | 42 | 0.510 |
Why?
| | Follow-Up Studies | 22 | 2024 | 2318 | 0.510 |
Why?
| | Pelvis | 1 | 2017 | 66 | 0.510 |
Why?
| | Stem Cell Transplantation | 11 | 2023 | 191 | 0.500 |
Why?
| | Osteoblasts | 6 | 2020 | 480 | 0.490 |
Why?
| | Thrombophilia | 4 | 2009 | 18 | 0.480 |
Why?
| | Tumor Microenvironment | 5 | 2024 | 274 | 0.460 |
Why?
| | Chromosome Deletion | 6 | 2023 | 138 | 0.450 |
Why?
| | Drug Resistance, Neoplasm | 7 | 2015 | 350 | 0.440 |
Why?
| | Animals | 19 | 2024 | 13526 | 0.430 |
Why?
| | Neoplasms | 3 | 2009 | 1334 | 0.430 |
Why?
| | Transplantation Conditioning | 7 | 2019 | 96 | 0.430 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2024 | 647 | 0.410 |
Why?
| | Receptor, Parathyroid Hormone, Type 1 | 1 | 2013 | 27 | 0.410 |
Why?
| | Polycythemia Vera | 1 | 2013 | 6 | 0.400 |
Why?
| | Positron-Emission Tomography | 4 | 2025 | 298 | 0.390 |
Why?
| | Hemostasis | 3 | 2008 | 55 | 0.390 |
Why?
| | Neovascularization, Pathologic | 4 | 2009 | 158 | 0.390 |
Why?
| | Diffusion Magnetic Resonance Imaging | 3 | 2025 | 133 | 0.380 |
Why?
| | Mutation | 6 | 2022 | 1337 | 0.370 |
Why?
| | Combined Modality Therapy | 17 | 2024 | 640 | 0.370 |
Why?
| | Neutropenia | 2 | 2023 | 113 | 0.370 |
Why?
| | Hematopoietic Stem Cells | 2 | 2012 | 189 | 0.340 |
Why?
| | Bone Neoplasms | 2 | 2010 | 188 | 0.340 |
Why?
| | Evolution, Molecular | 2 | 2021 | 97 | 0.330 |
Why?
| | Amyloidosis | 3 | 2009 | 83 | 0.330 |
Why?
| | Cytomegalovirus Infections | 2 | 2026 | 49 | 0.320 |
Why?
| | Doxorubicin | 7 | 2009 | 247 | 0.320 |
Why?
| | Immunotherapy, Adoptive | 4 | 2024 | 163 | 0.310 |
Why?
| | Mice | 11 | 2024 | 5982 | 0.300 |
Why?
| | Anti-Anxiety Agents | 1 | 2009 | 34 | 0.300 |
Why?
| | In Situ Hybridization, Fluorescence | 7 | 2023 | 266 | 0.300 |
Why?
| | Kaplan-Meier Estimate | 10 | 2019 | 487 | 0.300 |
Why?
| | Hemorrhagic Disorders | 1 | 2009 | 6 | 0.300 |
Why?
| | Pain | 2 | 2009 | 351 | 0.290 |
Why?
| | Cryoglobulinemia | 1 | 2008 | 13 | 0.290 |
Why?
| | Biopsy, Needle | 1 | 2009 | 181 | 0.290 |
Why?
| | Pulmonary Embolism | 1 | 2009 | 83 | 0.280 |
Why?
| | Analgesics | 1 | 2009 | 104 | 0.280 |
Why?
| | Collagen | 2 | 2020 | 215 | 0.280 |
Why?
| | Recurrence | 11 | 2024 | 694 | 0.280 |
Why?
| | Risk Assessment | 7 | 2023 | 1368 | 0.270 |
Why?
| | Hematologic Neoplasms | 2 | 2022 | 101 | 0.270 |
Why?
| | Cell Line, Tumor | 4 | 2023 | 1470 | 0.260 |
Why?
| | Cytomegalovirus | 2 | 2026 | 42 | 0.260 |
Why?
| | Farnesyltranstransferase | 1 | 2006 | 4 | 0.260 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2004 | 38 | 0.260 |
Why?
| | Virus Activation | 2 | 2026 | 49 | 0.250 |
Why?
| | Waldenstrom Macroglobulinemia | 2 | 2022 | 38 | 0.250 |
Why?
| | Osteolysis | 2 | 2022 | 74 | 0.250 |
Why?
| | Risk | 4 | 2014 | 306 | 0.250 |
Why?
| | Pyrroles | 2 | 2004 | 73 | 0.250 |
Why?
| | Neoplasms, Second Primary | 2 | 2024 | 75 | 0.250 |
Why?
| | Cell Proliferation | 8 | 2023 | 1031 | 0.250 |
Why?
| | Cell Differentiation | 4 | 2022 | 681 | 0.250 |
Why?
| | Time Factors | 11 | 2021 | 2991 | 0.240 |
Why?
| | Sirolimus | 1 | 2006 | 72 | 0.240 |
Why?
| | Logistic Models | 5 | 2018 | 947 | 0.240 |
Why?
| | Signal Transduction | 6 | 2021 | 1748 | 0.240 |
Why?
| | Chromosomes, Human, Pair 17 | 2 | 2017 | 35 | 0.230 |
Why?
| | Fluorodeoxyglucose F18 | 4 | 2021 | 182 | 0.220 |
Why?
| | Plasmacytoma | 2 | 2020 | 45 | 0.220 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2025 | 64 | 0.220 |
Why?
| | Enoxaparin | 1 | 2004 | 32 | 0.210 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2021 | 48 | 0.210 |
Why?
| | Remission Induction | 10 | 2021 | 221 | 0.210 |
Why?
| | Indoles | 2 | 2004 | 280 | 0.210 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2004 | 189 | 0.210 |
Why?
| | Prospective Studies | 9 | 2019 | 2411 | 0.200 |
Why?
| | Blood Coagulation | 1 | 2003 | 65 | 0.190 |
Why?
| | Bone Resorption | 2 | 2022 | 304 | 0.190 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2020 | 78 | 0.190 |
Why?
| | Hematopoietic Stem Cell Mobilization | 3 | 2008 | 63 | 0.180 |
Why?
| | Immunoglobulin Light Chains | 2 | 2017 | 90 | 0.180 |
Why?
| | Drug Approval | 1 | 2022 | 41 | 0.180 |
Why?
| | Immunoconjugates | 1 | 2022 | 37 | 0.180 |
Why?
| | Cell Cycle | 2 | 2021 | 237 | 0.180 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2012 | 630 | 0.180 |
Why?
| | Hemorrhage | 3 | 2009 | 226 | 0.180 |
Why?
| | Lymphoma, B-Cell | 1 | 2022 | 60 | 0.180 |
Why?
| | Chromosomal Instability | 2 | 2019 | 16 | 0.180 |
Why?
| | Epigenomics | 1 | 2021 | 76 | 0.170 |
Why?
| | Chromosomes, Human, Pair 13 | 5 | 2008 | 37 | 0.170 |
Why?
| | Patient Participation | 1 | 2022 | 72 | 0.170 |
Why?
| | T-Lymphocytes | 4 | 2024 | 321 | 0.170 |
Why?
| | SOXC Transcription Factors | 1 | 2021 | 13 | 0.170 |
Why?
| | Arkansas | 5 | 2021 | 2068 | 0.170 |
Why?
| | Calcium Phosphates | 1 | 2020 | 5 | 0.160 |
Why?
| | Odontoblasts | 1 | 2020 | 4 | 0.160 |
Why?
| | HL-60 Cells | 1 | 2020 | 19 | 0.160 |
Why?
| | U937 Cells | 1 | 2020 | 14 | 0.160 |
Why?
| | Etoposide | 5 | 2009 | 71 | 0.160 |
Why?
| | K562 Cells | 1 | 2020 | 42 | 0.160 |
Why?
| | Genes, Tumor Suppressor | 2 | 2021 | 73 | 0.160 |
Why?
| | NIH 3T3 Cells | 1 | 2020 | 52 | 0.160 |
Why?
| | MCF-7 Cells | 1 | 2020 | 65 | 0.160 |
Why?
| | Kidney Diseases | 2 | 2020 | 230 | 0.160 |
Why?
| | Mammals | 1 | 2020 | 58 | 0.160 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 502 | 0.160 |
Why?
| | Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.160 |
Why?
| | Protein C | 2 | 2011 | 20 | 0.160 |
Why?
| | Leukemia, Plasma Cell | 1 | 2020 | 35 | 0.160 |
Why?
| | Myelodysplastic Syndromes | 3 | 2007 | 87 | 0.160 |
Why?
| | beta 2-Microglobulin | 5 | 2008 | 39 | 0.160 |
Why?
| | Cisplatin | 6 | 2009 | 282 | 0.160 |
Why?
| | HeLa Cells | 1 | 2020 | 243 | 0.160 |
Why?
| | HEK293 Cells | 1 | 2020 | 235 | 0.150 |
Why?
| | Busulfan | 1 | 2019 | 18 | 0.150 |
Why?
| | Hematopoiesis, Extramedullary | 1 | 2019 | 9 | 0.150 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 112 | 0.150 |
Why?
| | Atrial Fibrillation | 1 | 2022 | 197 | 0.150 |
Why?
| | Imaging, Three-Dimensional | 2 | 2017 | 145 | 0.150 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 412 | 0.150 |
Why?
| | Genome-Wide Association Study | 1 | 2020 | 184 | 0.150 |
Why?
| | Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 9 | 0.150 |
Why?
| | Fractures, Compression | 1 | 2018 | 17 | 0.140 |
Why?
| | Healthcare Disparities | 1 | 2022 | 312 | 0.140 |
Why?
| | Predictive Value of Tests | 4 | 2009 | 934 | 0.140 |
Why?
| | Spleen | 1 | 2019 | 166 | 0.140 |
Why?
| | Genomic Instability | 2 | 2016 | 88 | 0.140 |
Why?
| | Fibrinolysis | 2 | 2009 | 6 | 0.140 |
Why?
| | Phosphotransferases | 1 | 2018 | 18 | 0.140 |
Why?
| | Cytokines | 3 | 2007 | 627 | 0.140 |
Why?
| | Blood Coagulation Factors | 2 | 2009 | 17 | 0.140 |
Why?
| | Bacteremia | 1 | 2019 | 87 | 0.140 |
Why?
| | Antineoplastic Agents, Alkylating | 6 | 2008 | 78 | 0.140 |
Why?
| | Adipocytes | 1 | 2018 | 131 | 0.140 |
Why?
| | Cell Line | 1 | 2020 | 1016 | 0.130 |
Why?
| | Gene Rearrangement | 1 | 2018 | 76 | 0.130 |
Why?
| | Cluster Analysis | 4 | 2012 | 237 | 0.130 |
Why?
| | Hexokinase | 1 | 2017 | 16 | 0.130 |
Why?
| | Metaphase | 4 | 2016 | 47 | 0.130 |
Why?
| | Heparin, Low-Molecular-Weight | 2 | 2007 | 22 | 0.130 |
Why?
| | Ultrasonography, Doppler | 2 | 2007 | 42 | 0.130 |
Why?
| | Renal Insufficiency | 4 | 2010 | 108 | 0.120 |
Why?
| | Calcium | 1 | 2018 | 373 | 0.120 |
Why?
| | Fibrinolytic Agents | 2 | 2007 | 132 | 0.120 |
Why?
| | Clonal Evolution | 1 | 2016 | 59 | 0.120 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 180 | 0.120 |
Why?
| | Tumor Burden | 3 | 2020 | 132 | 0.120 |
Why?
| | Gene Expression | 1 | 2018 | 618 | 0.120 |
Why?
| | Disease Models, Animal | 4 | 2016 | 1517 | 0.120 |
Why?
| | Bone Marrow Transplantation | 4 | 2022 | 110 | 0.110 |
Why?
| | Multivariate Analysis | 7 | 2021 | 598 | 0.110 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 228 | 0.110 |
Why?
| | Genes, Neoplasm | 1 | 2015 | 31 | 0.110 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2020 | 505 | 0.110 |
Why?
| | Immunotherapy | 2 | 2016 | 266 | 0.110 |
Why?
| | Gene Dosage | 1 | 2015 | 76 | 0.110 |
Why?
| | Salvage Therapy | 6 | 2006 | 138 | 0.110 |
Why?
| | Incidence | 2 | 2009 | 1085 | 0.110 |
Why?
| | Algorithms | 1 | 2018 | 667 | 0.110 |
Why?
| | Transcriptome | 3 | 2025 | 367 | 0.110 |
Why?
| | Osteoclasts | 3 | 2022 | 428 | 0.100 |
Why?
| | Cystatin M | 2 | 2024 | 17 | 0.100 |
Why?
| | Case-Control Studies | 4 | 2011 | 1212 | 0.100 |
Why?
| | Altitude | 1 | 2013 | 17 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 2 | 2017 | 1180 | 0.100 |
Why?
| | Janus Kinase 2 | 1 | 2013 | 27 | 0.100 |
Why?
| | Chromosomes, Human, Pair 11 | 3 | 2020 | 56 | 0.100 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 1723 | 0.100 |
Why?
| | STAT3 Transcription Factor | 2 | 2010 | 89 | 0.100 |
Why?
| | Models, Biological | 1 | 2016 | 737 | 0.100 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2018 | 87 | 0.100 |
Why?
| | Bone Density Conservation Agents | 2 | 2010 | 75 | 0.100 |
Why?
| | Mice, Inbred C57BL | 1 | 2018 | 1925 | 0.090 |
Why?
| | Cytogenetic Analysis | 6 | 2014 | 79 | 0.090 |
Why?
| | Creatinine | 2 | 2010 | 158 | 0.090 |
Why?
| | Viremia | 1 | 2012 | 23 | 0.090 |
Why?
| | Clone Cells | 2 | 2023 | 76 | 0.090 |
Why?
| | Models, Genetic | 2 | 2016 | 169 | 0.090 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2012 | 48 | 0.090 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2012 | 48 | 0.090 |
Why?
| | Viper Venoms | 1 | 2011 | 6 | 0.090 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2012 | 142 | 0.090 |
Why?
| | Epidemiologic Methods | 2 | 2008 | 47 | 0.090 |
Why?
| | NF-kappa B | 2 | 2018 | 327 | 0.090 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 7 | 0.080 |
Why?
| | Arsenicals | 1 | 2010 | 15 | 0.080 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 18 | 0.080 |
Why?
| | Oxides | 1 | 2010 | 21 | 0.080 |
Why?
| | Mutation Rate | 2 | 2021 | 36 | 0.080 |
Why?
| | Granulocyte Colony-Stimulating Factor | 2 | 2008 | 64 | 0.080 |
Why?
| | Hypercalcemia | 1 | 2010 | 34 | 0.080 |
Why?
| | Transplantation, Homologous | 4 | 2003 | 154 | 0.080 |
Why?
| | Cyclophosphamide | 4 | 2003 | 178 | 0.080 |
Why?
| | Janus Kinase 1 | 1 | 2010 | 16 | 0.080 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2010 | 22 | 0.080 |
Why?
| | Anemia | 1 | 2010 | 76 | 0.080 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2007 | 56 | 0.080 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2010 | 26 | 0.080 |
Why?
| | Administration, Oral | 2 | 2009 | 456 | 0.080 |
Why?
| | Proteinuria | 1 | 2010 | 38 | 0.080 |
Why?
| | Genomics | 2 | 2023 | 271 | 0.080 |
Why?
| | Alleles | 2 | 2021 | 277 | 0.080 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 84 | 0.080 |
Why?
| | Diphosphonates | 1 | 2010 | 92 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2008 | 1367 | 0.080 |
Why?
| | Lorazepam | 1 | 2009 | 13 | 0.080 |
Why?
| | Receptors, Retinoic Acid | 1 | 2009 | 22 | 0.080 |
Why?
| | Hyperhomocysteinemia | 1 | 2009 | 29 | 0.080 |
Why?
| | Oxycodone | 1 | 2009 | 27 | 0.080 |
Why?
| | Anesthesia, Local | 1 | 2009 | 18 | 0.080 |
Why?
| | Prednisone | 1 | 2009 | 101 | 0.070 |
Why?
| | Histones | 2 | 2021 | 318 | 0.070 |
Why?
| | Tretinoin | 1 | 2009 | 53 | 0.070 |
Why?
| | Hemostatic Techniques | 1 | 2009 | 32 | 0.070 |
Why?
| | Plasma Exchange | 1 | 2009 | 25 | 0.070 |
Why?
| | Transcription Factors | 2 | 2023 | 571 | 0.070 |
Why?
| | Vasculitis | 1 | 2008 | 28 | 0.070 |
Why?
| | Vincristine | 3 | 2003 | 89 | 0.070 |
Why?
| | Syndecan-1 | 3 | 2021 | 73 | 0.070 |
Why?
| | Biopsy | 3 | 2018 | 600 | 0.070 |
Why?
| | Radiopharmaceuticals | 2 | 2021 | 198 | 0.070 |
Why?
| | DNA Copy Number Variations | 2 | 2021 | 117 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2009 | 405 | 0.070 |
Why?
| | Cytogenetics | 1 | 2008 | 23 | 0.070 |
Why?
| | Bone Development | 1 | 2009 | 68 | 0.070 |
Why?
| | Staphylococcal Infections | 2 | 2019 | 271 | 0.070 |
Why?
| | Carrier Proteins | 1 | 2010 | 315 | 0.070 |
Why?
| | Pain Measurement | 1 | 2009 | 259 | 0.070 |
Why?
| | Platelet Aggregation | 1 | 2008 | 77 | 0.070 |
Why?
| | Thrombocytopenia | 1 | 2009 | 89 | 0.070 |
Why?
| | Double-Blind Method | 1 | 2009 | 729 | 0.070 |
Why?
| | Brain Diseases, Metabolic | 1 | 2007 | 5 | 0.070 |
Why?
| | Phlebography | 1 | 2007 | 55 | 0.070 |
Why?
| | Hyperammonemia | 1 | 2007 | 23 | 0.070 |
Why?
| | Myeloma Proteins | 1 | 2007 | 26 | 0.060 |
Why?
| | Antimetabolites | 1 | 2006 | 12 | 0.060 |
Why?
| | Chi-Square Distribution | 1 | 2007 | 291 | 0.060 |
Why?
| | Cell Communication | 2 | 2023 | 73 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 4 | 2007 | 1583 | 0.060 |
Why?
| | Partial Thromboplastin Time | 1 | 2006 | 15 | 0.060 |
Why?
| | Osteoprotegerin | 1 | 2006 | 53 | 0.060 |
Why?
| | Acetaminophen | 1 | 2009 | 277 | 0.060 |
Why?
| | Heterozygote | 1 | 2006 | 89 | 0.060 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2006 | 83 | 0.060 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2006 | 44 | 0.060 |
Why?
| | Models, Statistical | 1 | 2007 | 229 | 0.060 |
Why?
| | Pilot Projects | 1 | 2008 | 726 | 0.060 |
Why?
| | Age Factors | 3 | 2005 | 1136 | 0.060 |
Why?
| | Femur Head Necrosis | 1 | 2005 | 18 | 0.060 |
Why?
| | Apoptosis | 1 | 2010 | 1139 | 0.060 |
Why?
| | Neovascularization, Physiologic | 1 | 2005 | 86 | 0.060 |
Why?
| | Gene Deletion | 2 | 2003 | 279 | 0.060 |
Why?
| | Syndrome | 2 | 2019 | 248 | 0.060 |
Why?
| | ROC Curve | 1 | 2025 | 246 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 113 | 0.050 |
Why?
| | Ferritins | 1 | 2024 | 38 | 0.050 |
Why?
| | Glucuronidase | 1 | 2003 | 47 | 0.050 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 15 | 0.050 |
Why?
| | X-Ray Microtomography | 1 | 2024 | 80 | 0.050 |
Why?
| | DNA Methylation | 2 | 2020 | 592 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 145 | 0.050 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2024 | 58 | 0.050 |
Why?
| | DNA, Neoplasm | 2 | 2020 | 146 | 0.050 |
Why?
| | Antibodies | 1 | 2024 | 147 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2005 | 253 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2006 | 412 | 0.050 |
Why?
| | Discitis | 1 | 2003 | 11 | 0.050 |
Why?
| | Myeloproliferative Disorders | 1 | 2003 | 31 | 0.050 |
Why?
| | TNF Receptor-Associated Factor 3 | 1 | 2022 | 13 | 0.050 |
Why?
| | Rats | 1 | 2009 | 3162 | 0.050 |
Why?
| | Tumor Cells, Cultured | 3 | 2010 | 441 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2003 | 76 | 0.050 |
Why?
| | Platelet Count | 3 | 2008 | 68 | 0.050 |
Why?
| | Patients | 1 | 2022 | 52 | 0.050 |
Why?
| | Geography | 1 | 2022 | 65 | 0.050 |
Why?
| | Leukemia, Myeloid | 1 | 2002 | 40 | 0.050 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2022 | 32 | 0.050 |
Why?
| | Drug Interactions | 1 | 2002 | 196 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2022 | 52 | 0.050 |
Why?
| | Chromosome Disorders | 1 | 2002 | 32 | 0.040 |
Why?
| | United States Food and Drug Administration | 1 | 2022 | 93 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 371 | 0.040 |
Why?
| | Oncogenes | 1 | 2021 | 61 | 0.040 |
Why?
| | Patient Selection | 1 | 2023 | 273 | 0.040 |
Why?
| | Phylogeny | 1 | 2022 | 231 | 0.040 |
Why?
| | Hypothyroidism | 1 | 2002 | 58 | 0.040 |
Why?
| | Central Nervous System Neoplasms | 1 | 2002 | 69 | 0.040 |
Why?
| | RANK Ligand | 1 | 2022 | 188 | 0.040 |
Why?
| | Transcriptional Activation | 1 | 2021 | 128 | 0.040 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 92 | 0.040 |
Why?
| | Cohort Studies | 2 | 2020 | 1557 | 0.040 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 110 | 0.040 |
Why?
| | Chromatin | 1 | 2021 | 145 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 69 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 238 | 0.040 |
Why?
| | Cyclin D2 | 1 | 2020 | 21 | 0.040 |
Why?
| | Pyrimidines | 1 | 2022 | 205 | 0.040 |
Why?
| | Aneuploidy | 1 | 2020 | 17 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-maf | 1 | 2020 | 19 | 0.040 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2020 | 30 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2002 | 262 | 0.040 |
Why?
| | ras Proteins | 1 | 2020 | 64 | 0.040 |
Why?
| | Histone Code | 1 | 2020 | 32 | 0.040 |
Why?
| | Cyclin D1 | 1 | 2020 | 59 | 0.040 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2020 | 32 | 0.040 |
Why?
| | Genome, Human | 1 | 2021 | 121 | 0.040 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2020 | 76 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2016 | 774 | 0.040 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 17 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2022 | 233 | 0.040 |
Why?
| | Genetic Loci | 1 | 2020 | 48 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2007 | 1099 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2020 | 179 | 0.040 |
Why?
| | RNA, Messenger | 3 | 2010 | 1133 | 0.040 |
Why?
| | Genetic Variation | 1 | 2020 | 223 | 0.040 |
Why?
| | Neoplastic Stem Cells | 2 | 2015 | 90 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2022 | 221 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 180 | 0.040 |
Why?
| | Computational Biology | 1 | 2020 | 209 | 0.040 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2019 | 29 | 0.040 |
Why?
| | Pseudomonas Infections | 1 | 2019 | 54 | 0.040 |
Why?
| | Proline | 1 | 2018 | 31 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2021 | 423 | 0.040 |
Why?
| | Bone Marrow Cells | 2 | 2014 | 188 | 0.040 |
Why?
| | Recombinant Proteins | 2 | 2010 | 489 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 465 | 0.030 |
Why?
| | Fluorescent Dyes | 1 | 2018 | 90 | 0.030 |
Why?
| | Proteolysis | 1 | 2018 | 105 | 0.030 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2018 | 52 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 62 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2018 | 116 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2017 | 55 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 279 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2017 | 66 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2017 | 128 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2018 | 563 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 533 | 0.030 |
Why?
| | Cell Survival | 2 | 2010 | 600 | 0.030 |
Why?
| | Genes, ras | 1 | 2016 | 43 | 0.030 |
Why?
| | Genes, p53 | 1 | 2016 | 51 | 0.030 |
Why?
| | Mice, SCID | 2 | 2009 | 180 | 0.030 |
Why?
| | Chromosome Mapping | 2 | 2006 | 145 | 0.030 |
Why?
| | Glycolysis | 1 | 2016 | 76 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2016 | 98 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2016 | 148 | 0.030 |
Why?
| | Serum Albumin | 2 | 2008 | 56 | 0.030 |
Why?
| | Syndecans | 2 | 2006 | 37 | 0.030 |
Why?
| | Proteoglycans | 2 | 2006 | 86 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2018 | 1569 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2015 | 81 | 0.030 |
Why?
| | Interspersed Repetitive Sequences | 1 | 2014 | 7 | 0.030 |
Why?
| | Myocardium | 1 | 2017 | 471 | 0.030 |
Why?
| | Karyotype | 1 | 2014 | 22 | 0.030 |
Why?
| | Proportional Hazards Models | 2 | 2006 | 445 | 0.030 |
Why?
| | Membrane Glycoproteins | 2 | 2006 | 238 | 0.030 |
Why?
| | Transplantation Chimera | 2 | 2003 | 16 | 0.020 |
Why?
| | Neoplasm Staging | 2 | 2007 | 774 | 0.020 |
Why?
| | Infusions, Intravenous | 2 | 2003 | 211 | 0.020 |
Why?
| | RNA Interference | 1 | 2013 | 181 | 0.020 |
Why?
| | Viral Load | 1 | 2012 | 83 | 0.020 |
Why?
| | Graft vs Host Disease | 2 | 2003 | 93 | 0.020 |
Why?
| | Interferon Regulatory Factor-1 | 1 | 2010 | 14 | 0.020 |
Why?
| | United States | 1 | 2022 | 5409 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2010 | 24 | 0.020 |
Why?
| | Antiviral Agents | 1 | 2012 | 179 | 0.020 |
Why?
| | CDC2-CDC28 Kinases | 1 | 2010 | 11 | 0.020 |
Why?
| | Femur | 1 | 2010 | 133 | 0.020 |
Why?
| | Long-Term Care | 1 | 2010 | 50 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2010 | 214 | 0.020 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2010 | 60 | 0.020 |
Why?
| | Down-Regulation | 1 | 2010 | 344 | 0.020 |
Why?
| | Bone Diseases, Metabolic | 1 | 2010 | 79 | 0.020 |
Why?
| | Abnormalities, Multiple | 1 | 2010 | 166 | 0.020 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2010 | 187 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2009 | 124 | 0.020 |
Why?
| | Ploidies | 1 | 2008 | 10 | 0.020 |
Why?
| | Ligands | 1 | 2009 | 203 | 0.020 |
Why?
| | Rabbits | 1 | 2009 | 372 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2008 | 95 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 579 | 0.020 |
Why?
| | Hemoglobins | 1 | 2008 | 114 | 0.020 |
Why?
| | Age Distribution | 1 | 2007 | 175 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2010 | 1038 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2008 | 152 | 0.020 |
Why?
| | Mass Screening | 1 | 2010 | 362 | 0.020 |
Why?
| | Ammonia | 1 | 2007 | 89 | 0.020 |
Why?
| | Multigene Family | 1 | 2006 | 50 | 0.020 |
Why?
| | Blood Proteins | 1 | 2007 | 84 | 0.020 |
Why?
| | Bone Density | 1 | 2009 | 397 | 0.020 |
Why?
| | Brain | 2 | 2007 | 1350 | 0.020 |
Why?
| | Cyclin D | 1 | 2006 | 18 | 0.020 |
Why?
| | Cyclins | 1 | 2006 | 38 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2007 | 275 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2006 | 45 | 0.020 |
Why?
| | Radiography | 1 | 2007 | 476 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2006 | 146 | 0.010 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2007 | 208 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2006 | 169 | 0.010 |
Why?
| | Neoplasms, Experimental | 1 | 2006 | 112 | 0.010 |
Why?
| | Interferon-alpha | 1 | 2005 | 53 | 0.010 |
Why?
| | Survivors | 1 | 2006 | 120 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2006 | 561 | 0.010 |
Why?
| | Databases, Factual | 1 | 2007 | 742 | 0.010 |
Why?
| | Monosomy | 1 | 2003 | 5 | 0.010 |
Why?
| | Odds Ratio | 1 | 2005 | 567 | 0.010 |
Why?
| | Trisomy | 1 | 2003 | 34 | 0.010 |
Why?
| | History, 21st Century | 1 | 2003 | 60 | 0.010 |
Why?
| | Endothelial Growth Factors | 1 | 2003 | 11 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2003 | 15 | 0.010 |
Why?
| | Lymphokines | 1 | 2003 | 20 | 0.010 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2003 | 20 | 0.010 |
Why?
| | History, 20th Century | 1 | 2003 | 97 | 0.010 |
Why?
| | Stem Cell Factor | 1 | 2003 | 7 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2003 | 158 | 0.010 |
Why?
| | Probability | 1 | 2003 | 171 | 0.010 |
Why?
| | Interphase | 1 | 2003 | 9 | 0.010 |
Why?
| | Lymphocyte Transfusion | 1 | 2003 | 10 | 0.010 |
Why?
| | Diploidy | 1 | 2003 | 25 | 0.010 |
Why?
| | Leukocyte Count | 1 | 2003 | 71 | 0.010 |
Why?
| | Back Pain | 1 | 2003 | 40 | 0.010 |
Why?
| | Interferons | 1 | 2002 | 39 | 0.010 |
Why?
| | Cell Count | 1 | 2003 | 141 | 0.010 |
Why?
| | Sex Factors | 1 | 2005 | 747 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2003 | 107 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2003 | 370 | 0.010 |
Why?
| | Thyroid Function Tests | 1 | 2002 | 28 | 0.010 |
Why?
| | Thyrotropin | 1 | 2002 | 49 | 0.010 |
Why?
| | Prevalence | 1 | 2005 | 1034 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2002 | 193 | 0.010 |
Why?
| | Neutrophils | 1 | 2003 | 153 | 0.010 |
Why?
| | Tissue Donors | 1 | 2003 | 130 | 0.010 |
Why?
| | Cell Division | 1 | 2002 | 289 | 0.010 |
Why?
| | Reoperation | 1 | 2003 | 476 | 0.010 |
Why?
| | Acute Disease | 1 | 2002 | 393 | 0.010 |
Why?
| | Up-Regulation | 1 | 2002 | 456 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2003 | 830 | 0.010 |
Why?
|
|
Zangari's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|